Kornimate/medical-research-clean huggingface dataset:
effect of sugar-free chewing gum containing tulsi extract on salivary streptococcus mutans in a group of children

Conditions: Dental Caries in Children

Summary: the goal of this clinical trial was to explore how adding tulsi extract, a natural plant substance, to chewing gum affects the levels of streptococcus mutans, type of bacteria that cause dental caries, in the saliva of children aged 4 to 11 years. participants should not use removable prosthetics or orthodontic appliances and had had not used antibiotics in the 2 weeks preceding sample collection. we want to answer this main question: can chewing gum with tulsi extract significantly reduce the number of streptococcus mutans bacteria in children's saliva? participants tasks: * children were asked to chew gum containing tulsi extract for 5 minutes and then dispose of the gum. * two salivary samples were collected from each child: one before gum chewing and another 30 minutes after disposing the gum. researchers compared streptococcus mutans counts in saliva before and after gum chewing to determine if there is a significant reduction in bacterial colonies.

this interventional clinical trial aimed to assess the antimicrobial effect of tulsi extract incorporated into chewing gum on the salivary streptococcus mutans count in a group of children aged 4 to 11 years. the study enrolled 32 systemically healthy children who met specific criteria, including the absence of removable prosthetics or orthodontic appliances and no recent history of antibiotic use in the preceding 2 weeks. participants and methods: a sample of 33 children within the age range of 4 to 11 years was selected. the participants were systemically healthy, without removable prosthetics or orthodontic appliances, and had no recent history of antibiotic use in the previous 2 weeks. to standardize saliva collection conditions, samples were collected between 9-10 am in the morning. children were instructed not to eat or drink anything (except water) 1 hour before saliva collection to maintain consistency in the samples. participants were then asked to spit into sterile containers as the method of saliva collection. subsequently, they were instructed to masticate gum containing tulsi extract for a duration of 5 minutes and discard the gum. two salivary samples were collected from each participant: one before commencing gum chewing and another 30 minutes after the conclusion of chewing gum for 5 minutes. the samples were streaked onto mitis salivarius agar plates and incubated at 37°c for 24 hours. streptococcus mutans colonies were then counted to assess the change in bacterial count.

Eligibility criteria:
inclusion criteria: 1. children aged between 4 and 12 years old. 2. no fixed or removable orthodontic appliances or removable prostheses. 3. systemically healthy patients. 4. no history of recent antibiotic administration (previous 2 weeks). exclusion criteria: 1. history of using antimicrobial mouthwash (previous 12 hours). 2. history of fluoride treatment (previous 2 weeks).

Keywords: caries prevention streptococcus mutans
neva one registry study

Conditions: Acute Ischemic Stroke

Summary: a prospective, open label study designed to assess the safety, performance and efficacy of thrombus removal in subjects presenting with acute ischemic stroke with the neva stent retrievers.

this is a prospective, open label, multi-center registry designed to assess the safety, performance and efficacy of the neva stent retriever in the treatment of large vessel occlusion strokes. up to 600 subjects will be enrolled at up 30 sites.

Eligibility criteria:
inclusion criteria: only subjects already treated with the neva thrombectomy devices can be considered for enrollment. 1. age ≥18 2. nihss score ≥ 6 3. pre-stroke mrs score ≤ 1 4. intracranial arterial occlusion of the distal intracranial carotid artery or middle cerebral artery (m1/m2), anterior cerebral artery (aca), posterior cerebral artery (pca), basilar artery, or vertebral artery demonstrated with dsa. 5. thrombectomy procedure can be initiated within 24 hours from symptom onset (defined as time last known well \[tlkw\]) 6. imaging inclusion criteria: the patient should have confirmed lvo and salvageable penumbra. any automated software for determine the volume of viable tissue is acceptable. patient selection should follow the following guidelines: * aspects 6-10 if treatment started 0-6 hours from tlkw * aspects 8-10 if treatment started 6-24 hours from tlkw * ischemic core ≤ 50 cc 7. subject or legal representative is able and willing to give informed consent within 72 hours after the intervention (may use independent physician consent in this timeframe and gain subject or legal representative consent later than 72 hours). exclusion criteria: 1. pre-existing medical neurological or psychiatric disease that would confound the neurological or functional evaluations, e.g. dementia with prescribed anti-cholinesterase inhibitor (e.g. aricept). 2. cardiopulmonary resuscitation, significant cardiac arrhythmia, evidence of ongoing myocardial infarction, concern for pre- treatment pulmonary aspiration. 3. clinical symptoms suggestive of bilateral stroke or stroke in multiple territories 4. cerebral vasculitis 5. history of severe allergy to contrast medium. 6. known allergy to neva materials (nitinol, stainless steel) 7. suspicion of aortic dissection, septic embolus, or bacterial endocarditis 8. systemic infection 9. significant mass effect with midline shift 10. evidence of intracranial tumor (except small meningioma) 11. inability to deploy neva device for at least one pass for any other reason 12. life expectancy less than 6 months 13. any other condition that, in the opinion of the investigator, precludes an endovascular procedure or poses a significant hazard to the subject if an endovascular procedure was performed.

Keywords: thrombus stroke
retrospective study of the biomechanical properties of large allografts

Conditions: Bone Cancer

Summary: primary objectives: 1. to evaluate the material properties, histomorphometric indices, bone mineral density (bmd), and presence of microfractures in retrieved large allograft cortical bone specimens removed from orthopaedic oncology patients. 2. to correlate physical properties to patient demographics and medical treatment received.

allograft surgery: as a standard of care, you will be having surgery to remove allograft tissue that has failed or because there were other complications following your earlier transplant. you will be separately consented for this surgery, which will describe the procedure and its risks in detail. tissue research: if you agree to take part in this study, leftover sample of the removed allograft bone will be collected and used to learn about the properties (such as bone strength, bone density, and new bone formation) of the removed transplant tissue. this tissue will be stored at the university of arkansas for use in this study. any remaining leftover tissue will be destroyed by the end of december 2011. data collection: before you have surgery, you will have an x-ray. this is also part of standard of care. if you take part in this study, this x-ray will be used to learn about the properties of the transplant tissue. all other information will be coming from your medical record, either from your past visits or as a result of your surgery. the information being collected will include information about your graft during the time it was within your body and observations made by your surgeon at its removal. length of study: your participation in this study will be over after your tissue and data are collected. this is an investigational study. up to 200 patients will be enrolled on this multicenter study. up to 20 will be enrolled at m. d. anderson.

Eligibility criteria:
inclusion criteria: * patients that require retrieval of a previously implanted large allograft. exclusion criteria: * none

Keywords: bone cancer allograft retrieval allograft bone bone mineral density
effect of txa on reducing bruising after filler injection

Conditions: Facial Filler Injections; Hyaluronic Acid; Tranexamic Acid

Summary: the goal of this clinical trial is to look at the effect tranexamic acid (txa) may have on reducing bruising, swelling, and pain after facial filler injection. the main question it aims to answer is: * does the addition of txa to hyaluronic acid (ha) reduce bruising, swelling, and tenderness after ha injection? participants will receive the study medication along with the standard facial filler injection and complete surveys.

the overall purpose of this study is to evaluate the safety and efficacy of co-administration of txa with ha in reducing swelling, bruising and pain after facial injection. researchers will do this by comparing ha to ha+txa in participants undergoing facial filler injections. participants undergoing facial filler injections almost always have the same type of injection performed bilaterally in order to maintain symmetry. this provides a unique opportunity where participants can serve as their own controls. therefore, researchers have designed this as a half face study. participants will be injected with ha on half of their face and the other half of the face will be injected with ha+txa. researchers will then assess swelling, bruising, pain, and overall satisfaction using participant self-reported surveys, physician surveys, and review of medical records.

Eligibility criteria:
inclusion criteria: * age equal to or greater than 18 but less than or equal to 89 years. * participants interested in facial filler (ha) injection. * english speaking. exclusion criteria: * minors or under the age of 18 * participant over the age of 89 * pregnant or breast-feeding women * individuals unable to give consent due to another condition such as impaired decision-making capacity. * individuals with a history of a thrombotic event (dvt, pe, stroke, mi) or genetic disorder that increases risk of thrombosis * concurrent use of estrogen * participants undergoing unilateral facial filler (ha) injection * participants with history of hypersensitivity to txa or any of the other ingredients * participants that are on current therapeutic anticoagulation therapy and aspirin use * participants with stage 2 or greater renal failure * participants on hemo- or peritoneal dialysis * history of diabetes or seizures * current tobacco smokers * acquired defective color vision
overlooked population at risk for ain.

Conditions: High Grade Cervical Dysplasia; Cervical Cancer

Summary: the purpose of this study is to determine the possibility and compliance of performing anal pap smear and human papilloma virus (hpv) dna testing on women with high grade lower genital tract dysplasia or cervical cancer and determining the prevalence of anal dysplasia in this population using a high-resolution anoscopy (hra). in addition, it is being done to potentially develop screening, diagnostic and treatment protocol for anal dysplasia in women with high-grade lower genital tract dysplasia or cervical cancer.

anal cancer incidence is increasing and although women compose more than half of all cases and those with hpv related lower genital tract dysplasia/malignancy have an even greater risk screening is currently not recommended. we therefore propose performing a prospective cohort study to determine the prevalence of anal dysplasia in women with high-grade lower genital tract dysplasia using high-resolution anoscopy hra. this will then potentially lead to the development of a screening, diagnosis and treatment schema that can be implemented in all women with high-grade lower genital tract dysplasia. this study can potentially have a high impact on health delivery in women at high risk for anal cancer as this can transform the current treatment of anal cancer to a preventive screening program. this can later be implemented throughout ontario and in all centers that treat women with cervical dysplasia. the incidence of anal intraepithelial neoplasm (ain also known as anal cancer) has increased in ontario over the last 20 years. two-thirds of the cases are found in women. the average time between diagnosis of anal cancer and previous cervical dysplasia or cancer is approximately 20 years. this study is giving the opportunity to detect and treat pre-invasive lesions and potentially prevent the development of anal cancer. currently, no screening, diagnosis or treatment recommendation for anal dysplasia found in women with high-grade lower genital tract dysplasia.

Eligibility criteria:
inclusion criteria: * women ≥ 40 years old * previous or current high grade cervical dysplasia or cervical cancer exclusion criteria: * women ≥ 40 years old because the median time between the diagnosis of anal cancer and previous cervical cancer is approximately 20 years. * chemotherapy or radiation therapy within the last 6 months

Keywords: cervical
clinical interpretation and cutoff scores for abilhand questionnaire in rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: in individuals with rheumatoid arthritis, the most significant symptom is the loss of manual ability and function in the hands. in rheumatoid arthritis, where patient-reported assessment scales are frequently used, hand skills should be evaluated with an ideal questionnaire that best represents hand activities. the abilhand-ra questionnaire possesses all these features, being a short and easily fillable survey. the aim is to determine of clinically significant cutoff scores for perceived manual ability evaluated by abilhand corresponding to observed and perceived upper extremity assessments in individuals with rheumatoid arthritis.


Eligibility criteria:
inclusion criteria: * people between the ages of 20-65, who were diagnosed with ra according to acr criteria by the pau rheumatology clinic and who volunteered to participate in the study, will be included. exclusion criteria: * patients with ra who have a neurological disease that may affect hand functions (peripheral nerve lesion, trauma, operation, cerebrovascular accident), a psychiatric disease that affects cooperation, heart failure and lung pathology that affect daily living activities, and those with other concurrent autoimmune and rheumatic diseases.
mobile application to improve nutritional counseling provided by primary care physicians for hypertension.

Conditions: Hypertension

Summary: the purpose of this study is to investigate whether the use of a mobile app could improve knowledge and practice in nutrition counseling performed by primary care physicians in brazil.

to optimize the nutritional care in the context of the limitations of available time and knowledge in medical practice, the present study proposes to develop a tool of nutritional guidelines for hypertension, easily accessible, based on evidence, and then evaluate its use among primary care physicians registered in a center telehealth. the use of the mobile application tool will aim to improve the nutritional counseling, helping with prevention of other chronic diseases in primary care context.

Eligibility criteria:
inclusion criteria: * primary care physicians registered in telessaúders (center for telehealth) * primary care physicians who use smartphone or tablet exclusion criteria: * not to work in primary care

Keywords: nutritional knowledge nutritional counseling
comparative effects of motor control and isolated strengthening lumbar exercises on functional outcomes in patients with chronic low back pain

Conditions: Chronic Low-back Pain

Summary: comparative effects of motor control and isolated strengthening lumbar exercises on functional outcomes in patients with chronic low back pain

as there is an increasing population of low back pain because of the stress and workload that lead to poor posture. poor posture leads to tightening of flexor muscles and weakness of lumbar extensors that knowns as lower cross syndrome and it will become the chronic low back pain if not treated on time. most of the therapist only work on the pain management but not focus on the functional outcome of the patient so the isolated lumbar extensor strengthening exercises and motor control exercises should be evaluated to know the effectiveness in improving the functional outcome of patients. to compare the effects of motor control and isolated strengthening lumbar exercises on functional outcome in patients with chronic low back pain. a randomized controlled trial with a sample of 35 patients with chronic low back pain will be taken from physiotherapy opds of madinah teaching hospital, allied hospital, in motion physiotherapy clinic and the physio rehab clinic. participants will be randomly divided into two groups using convenient sampling technique. both groups will be experimental groups. patients in group a will do motor control exercises. patients in group b will do isolated strengthening lumbar exercises. hot pack will be applied for 15 minutes and ultrasound therapy (1mhz) for 3-5 minutes as baseline treatment in both groups. patients will be included based on inclusion and exclusion criteria. assessment will be done by using nprs and oswestry disability index questionnaire.

Eligibility criteria:
inclusion criteria: * lbp for more than 3 months both male and females. age between 20-50 years old. moderate to severe pain (vas; 3-7) currently seeking care for lbp. exclusion criteria: * spinal surgery pregnancy prostatectomy engaged in any sports activities any evidence of nerve root compression
a study to investigate the pharmacokinetics and pharmacodynamics of ro7234292 (rg6042) in csf and plasma, and safety and tolerability following intrathecal administration in patients with huntington's disease

Conditions: Huntingtons Disease

Summary: study bp40410 is an open-label, adaptive multiple-dose clinical study designed to characterize the pk of ro7234292 (rg6042) in plasma and csf as well as the acute time course and recovery profile of csf mhtt lowering in response to ro7234292 (rg6042) treatment after intrathecal (it) administration of ro7234292 (rg6042) to patients with manifest hungtington's disease (hd).


Eligibility criteria:
inclusion criteria: * manifest hd diagnosis * independence scale score of \>=70. * genetically confirmed disease by direct deoxyribonucleic acid testing with a cytosine, adenine, and guanine base sequence found in dna which is translated into glutamine (cag) age product (cap) score \> 400. * ability to read the words "red," "blue," and "green" in the patient's native language. * ability to walk unassisted without a cane or walker and move about without a wheelchair on a daily basis as reviewed at screening and baseline visit. * ability to undergo and tolerate mri scans. exclusion criteria: * history of attempted suicide or suicidal ideation with plan (i.e., active suicidal ideation) that required hospital visit and/or change in level of care within 12 months prior to screening. * current active psychosis, confusional state, or violent behavior. * any serious medical condition or clinically significant laboratory, vital signs, or ecg abnormalities at screening that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study. * clinical diagnosis of chronic migraines or history of low pressure headache after lumbar puncture requiring hospitalization or blood patch. * treatment with investigational therapy within 4 weeks prior to screening or 5 drug elimination half-lives of investigational therapy, whichever is longer. * concurrent or planned concurrent participation in any interventional clinical study, including explicit pharmacological and non-pharmacological interventions. observational studies are acceptable. * unable or unsafe to perform lumbar puncture on the patient. * previous lumbar surgery that is likely, in the opinion of the investigator or surgical team, to make it catheter insertion or it injection unduly difficult or hazardous. * poor peripheral venous access. * scoliosis or spinal deformity making it injection not feasible in the outpatient setting. * preexisting intra-axial or extra-axial lesions as assessed by a centrally read mri scan during the screening period.
a community intervention study of female pelvic floor condition and knowledge of pelvic floor exercises

Conditions: Behavioural

Summary: the aims of the study were to attempt to answer the following questions; what proportion of women know how to and are able to exercise their pelvic floor and for those who cannot can they be trained and motivated to do so. this was a nested design comprising a prospective cohort study together with a controlled trial intervention after baseline assessment in the cohort study for a defined at-risk group.


Eligibility criteria:
inclusion criteria: able to give consent aged above 18 years modified oxford score, mos, ≤ 2 exclusion criteria: unable to give consent -

Keywords: female pelvic floor condition pelvic floor training supervised pelvic floor training practice nurse nurse specialist
study evaluating the effect of tc-6499 on gastric emptying time in diabetic subjects with gastroparesis

Conditions: Gastroparesis

Summary: gastroparesis, also referred to as delayed gastric emptying, is a debilitating, chronic disorder that slows or stops the passage of food from the stomach to the small intestine. the purpose of this study is to test whether tc-6499 is safe and effective at reducing gastric emptying time in diabetic subjects with gastroparesis.

this is a 4-way crossover study to assess the effect of tc-6499 on gastric emptying time in diabetic subjects with gastroparesis. the length of study participation for a subject is up to 50 days. during screening, eligible subjects will complete an oral 13-c-spirulina breath test also known as the gastric emptying breath test (gebt). during the treatment period, subjects will complete 4 overnight drug assessment visits (treatment arms) where they will receive a randomized single dose of study drug and the gebt. each overnight visit will be separated by approximately 7 days. at least 18 subjects will be randomized and complete all 4 dosing arms (actual = 23 randomized subjects and 21 completing all 4 arms of the crossover).

Eligibility criteria:
inclusion criteria: * a diagnosis of gastroparesis or symptoms consistent with gastroparesis for at least 6 months (and gastroparesis cardinal symptoms index total score \>22) * gastroparesis confirmed using the gebt * type 1 or type 2 diabetes with a hemoglobin a1c ≤ 10% * fasting blood glucose (finger stick) ≤ 275 mg/dl prior to each gebt * body mass index (bmi) ≤ 40 * willingness to remain in clinical research facility for the protocol-required days of treatment and study procedures * willingness to use a double barrier method of birth control (except post-menopausal females) * able to understand study procedures and provide written informed consent exclusion criteria: * history of abdominal surgery including gastric banding procedure * chronic parenteral feeding or feeding through a gastrostomy or jejunostomy tube * persistent daily vomiting * a history of eating disorder * recent history of poor control of diabetes * acute severe gastroenteritis * have implanted or use any type of gastric electric stimulator * use of opiates, anticholinergic medications, glp-1 mimetics or amylin analogs * use of medications potentially influencing upper gastrointestinal motility or appetite * allergies or intolerance to egg, wheat, milk, or algae * pregnant or lactating females * presence of a clinically significant medical condition at any time during the study * presence of clinically significant abnormalities in laboratory findings, physical exam findings or vital signs * participated in an investigational drug study within 30 days of screening